Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus.
The authors prospectively followed 14 patients treated with thalidomide for cutaneous lupus erythematosus (CLE), in order to evaluate the occurrence of peripheral neuropathy (PN) and to assess whether PN correlates with thalidomide dose. The patients were followed for up to 24 months with neurologic and electrophysiologic evaluations. Seven patients (50%) developed sensory axonal PN. The median time free from PN was 14 months. PN occurred after 10 months in the majority of patients. No correlations were found between thalidomide cumulative dose and occurrence of PN (Mann-Whitney U test; p > 0.16).
Briani
C
C
Department of Neurosciences, Rheumatology Division, University of Padova, Italy. chiara.briani@unipd.it
Zara
G
G
Rondinone
R
R
Della Libera
S
S
Ermani
M
M
Ruggero
S
S
Ghirardello
A
A
Zampieri
S
S
Doria
A
A
D000328:Adult; D004594:Electrophysiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy*; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000175:diagnosis / Q000209:etiology*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis; D011446:Prospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D013792:Thalidomide